NASDAQ:CRVS

Corvus Pharmaceuticals (CRVS) Stock Price, News & Analysis

Corvus Pharmaceuticals logo
$9.66 -0.35 (-3.48%)
Closing price 03:59 PM Eastern
Extended Trading
$9.66 +0.00 (+0.03%)
As of 04:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Corvus Pharmaceuticals Stock (NASDAQ:CRVS)

Advanced

Key Stats

Today's Range
$9.56
▼
$10.04
50-Day Range
$9.38
▼
$13.44
52-Week Range
$6.39
▼
$26.95
Volume
927,517 shs
Average Volume
1.82 million shs
Market Capitalization
$815.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.83
Consensus Rating
Moderate Buy

Company Overview

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines that target the immune system to treat cancer and immune-related diseases. The company is based in Burlingame, California, and its work centers on therapies in clinical development rather than marketed products.

Its lead candidate, soquelitinib (also known as CPI-818), is an oral inhibitor of interleukin-2-inducible T-cell kinase, or ITK. Corvus is developing the drug for T-cell lymphoma and has also explored its potential in inflammatory and autoimmune conditions, including atopic dermatitis.

Corvus was founded in 2014 and is led by co-founder Richard A. Miller, who serves as president and chief executive officer. The company’s development activities are focused on advancing its drug candidates through clinical research.

AI Generated. May Contain Errors.

Corvus Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
56th Percentile Overall Score

CRVS MarketRank™: 
2.776481888035 of 5 stars

Corvus Pharmaceuticals scored higher than 56% of companies evaluated by MarketBeat, and ranked 402nd out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Corvus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 1 strong buy rating, 6 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Corvus Pharmaceuticals has a consensus price target of $32.83, representing about 239.8% upside from its current price of $9.66.

  • Amount of Analyst Coverage

    Corvus Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

  • Read more about Corvus Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Corvus Pharmaceuticals are expected to decrease in the coming year, from ($0.81) to ($1.14) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Corvus Pharmaceuticals is -13.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Corvus Pharmaceuticals is -13.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Corvus Pharmaceuticals has a P/B Ratio of 3.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    26.29% of the float of Corvus Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Corvus Pharmaceuticals has a short interest ratio ("days to cover") of 18.85, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Corvus Pharmaceuticals has recently decreased by 1.16%, indicating that investor sentiment is improving.
  • Dividend Yield

    Corvus Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Corvus Pharmaceuticals does not have a long track record of dividend growth.

  • News Sentiment

    Corvus Pharmaceuticals has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for Corvus Pharmaceuticals this week, compared to 4 articles on an average week.
  • Search Interest

    3 people have searched for CRVS on MarketBeat in the last 30 days.
  • MarketBeat Follows

    5 people have added Corvus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.
  • Net Insider Buying

    Over the last three months, insiders have purchased a net $50,478.00 in company stock, which represents 0.0062% of the company's market cap.

  • Insider Buying vs. Insider Selling

    In the past three months, Corvus Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $50,478.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    19.70% of the stock of Corvus Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    46.64% of the stock of Corvus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Corvus Pharmaceuticals' insider trading history.
Receive CRVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corvus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CRVS Stock News Headlines

CFA: Bank of America Said THIS
On January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savings account… The digital dollar is inevitable. Think about what this means... When the digital dollar goes live, every dollar you saved could suddenly be trackable at the transaction level. Imagine the worst case scenario: You’re now subject to new digital withdrawal limits and spending restrictions. Your account can be frozen remotely without court approval. But here's what Bank of America didn't say: There's still a way to protect your wealth before this digital prison locks. While everyone else gets trapped in the digital system, my research team has been positioning members outside that reach… completely under their own control. No government tracking. No withdrawal limits. No remote freezing.tc pixel
FY2026 Earnings Estimate for CRVS Issued By HC Wainwright
See More Headlines

CRVS Stock Analysis - Frequently Asked Questions

Corvus Pharmaceuticals' stock was trading at $7.70 at the beginning of 2026. Since then, CRVS stock has increased by 25.5% and is now trading at $9.6620.

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) announced its quarterly earnings results on Thursday, November, 5th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by $0.03.
Read the conference call transcript
.

Corvus Pharmaceuticals (CRVS) raised $75 million in an initial public offering on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Credit Suisse and Cowen and Company served as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers.

Corvus Pharmaceuticals' top institutional shareholders include State Street Corp (3.95%), Fisher Asset Management LLC (1.24%), Goldman Sachs Group Inc. (0.77%) and Blue Owl Capital Holdings LP (0.43%). Insiders that own company stock include Peter A Thompson, Richard A Md Miller, William Benton Jones, David Scott Moore and Jeffrey Arcara.
View institutional ownership trends
.

Shares of CRVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Corvus Pharmaceuticals investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Vaxart (VXRT), Inovio Pharmaceuticals (INO), Palantir Technologies (PLTR), Tesla (TSLA) and Delta Air Lines (DAL).

Company Calendar

Last Earnings
11/05/2026
Today
11/20/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CRVS
CIK
1626971
Fax
N/A
Employees
37
Year Founded
2014

Price Target and Rating

High Price Target
$42.00
Low Price Target
$27.00
Potential Upside/Downside
+239.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.71)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$15.28 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-34.98%
Return on Assets
-32.67%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
13.38
Quick Ratio
13.38

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
$0.12 per share
Price / Cash Flow
80.39
Book Value
$2.47 per share
Price / Book
3.91

Miscellaneous

Outstanding Shares
84,353,000
Free Float
67,735,000
Market Cap
$815.02 million
Optionable
Optionable
Beta
1.57

Social Links

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

This page (NASDAQ:CRVS) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners